Piper Sandler Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $25
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight and lowers the price target from $72 to $25.
Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight and lowers the price target from $72 to $25.